

Treatment Group (Comparison to Irbesartan 300 mg)	Number of Subjects in Analysis		Number (%) of Subjects Achieving FPPE		Percentage Difference (Sparsentan- Irbesartan) (95% CI)	Nominal p-value ^a
	Irbesartan	Sparsentan	Irbesartan	Sparsentan	---	---
Sparsentan 200 mg, 400 mg, and 800 mg (pooled)	32	64	3 (9.38)	18 (28.13)	18.75 (1.46, 36.04)	0.040
Sparsentan 400 mg and 800 mg (pooled)	25	51	3 (12.00)	16 (31.37)	19.37 (-1.62, 40.37)	0.092
Sparsentan 400 mg	17	21	3 (17.65)	8 (38.10)	20.45 (-12.44, 53.33)	0.282
Sparsentan 800 mg	8	30	0	8 (26.67)	26.67 (2.93, 50.41)	0.164
Sparsentan 200 mg	7	13	0	2 (15.38)	15.38 (-15.22, 45.99)	0.521

Abbreviations: CI = confidence interval; FPPE = focal segmental glomerulosclerosis partial response endpoint; UP/C = urine protein to creatinine ratio (g/g)

FPPE is defined as a UP/C value of ≤ 1.5 g/g AND a $>40\%$ reduction from baseline in UP/C.

Discrete outcomes are compared using a Fisher's Exact test. Wald asymptotic 95% confidence intervals with continuity correction are presented for the difference in proportions.

^a Nominal p-values shown due to multiple-comparisons adjustment procedure

Source: Table 14.2.2.1.1 15AUG2019